Vigil Neuroscience, Inc. (VIGL)
NASDAQ: VIGL · Real-Time Price · USD
8.05
0.00 (0.00%)
At close: Aug 1, 2025, 4:00 PM
8.06
+0.01 (0.12%)
After-hours: Aug 1, 2025, 5:30 PM EDT
ANSYS Employees
Vigil Neuroscience had 69 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
69
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,256,942
Market Cap
383.80M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 69 | 0 | - |
| Dec 31, 2023 | 69 | 13 | 23.21% |
| Dec 31, 2022 | 56 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VIGL News
- 18 days ago - VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc. - VIGL - Business Wire
- 2 months ago - Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP - GlobeNewsWire
- 2 months ago - Sanofi to Buy Vigil Neuroscience for About $470 Million - WSJ
- 2 months ago - Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi - GlobeNewsWire
- 2 months ago - Sanofi to acquire Vigil Neuroscience in $470 million deal - Reuters
- 2 months ago - Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer's disease to the neurology pipeline - GlobeNewsWire
- 3 months ago - Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates - GlobeNewsWire
- 4 months ago - Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference - GlobeNewsWire